Topical Group: 5:30-6:30 P.M. -- Note early starting time.
Social Hour: 6:00- 7:00 P.M.
Dinner: 7:00 P.M.
Meeting: 8:00 P.M.
Abstract:
The immunoassay diagnostics industry can trace its roots to
1959 when Rosalyn Yalow and Solomon Berson described the first
radioimmunoassay for plasma insulin. Harnessing the antibody molecule, with its
firm yet selective handshake, was the insight that made immunoassays
possible. The fundamental principles, elucidated by Yalow and Berson,
remain unchanged and Rosalyn Yalow was awarded the Nobel Prize for
Medicine in 1977. Over the last 40 years, the use of immunoassays in medicine
has grown into a multibillion-dollar industry.
Development of a commercially successful immunoassay requires both an
understanding of the principles governing antibody performance and an
awareness of the assay characteristics important to the user. First and
foremost, the immunoassay must have good sensitivity, specificity,
accuracy and precision. The assay must measure what was intended and do it
with good reproducibility. To serve the fast-paced and cost conscious
medical laboratory, the assay reagents must also have good lot-to-lot
consistency, excellent shelf life and be available with an instrument
system that delivers high throughput and data handling capabilities.
Through the use of real-world examples, Dr. Grenier will describe the
development process for state-of-the-art immunoassays.
Biography:
Dr. Grenier has been with Abbott for 17 years, during which
he has worked on various aspects of the development of in vitro
diagnostic immunoassays. Over his career he has successfully launched
thirteen new immunoassays into worldwide markets. He has authored numerous
technical papers and holds five U.S. patents. He received his Ph.D. in
Biochemistry from Michigan State University and held NIH and American
Cancer Society Postdoctoral Fellowships at UC San Diego.